Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 10/20 | 0.44 |
| ▸ | EGFR | P00533 | 5/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.37 |
| ▸ | ITK | Q08881 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15337712 | 1.00 | BCL6 (0.44) | BCL6EGFRTBK1ITKBTK | |
| SCHEMBL15337489 | 0.93 | BCL6 (0.44) | BCL6EGFRITKBTKNCOR2 | |
| SCHEMBL19830188 | 0.93 | EGFR (0.39) | BCL6EGFRTBK1ITKBTK | |
| SCHEMBL17708203 | 0.93 | EGFR (0.39) | BCL6EGFRTBK1ITKBTK | |
| SCHEMBL15337482 | 0.92 | ULK1 (0.40) | BCL6EGFRTBK1 | |
| SCHEMBL15337710 | 0.92 | ULK1 (0.40) | BCL6EGFRTBK1 | |
| SCHEMBL15337651 | 0.92 | ULK1 (0.40) | BCL6EGFRTBK1 | |
| SCHEMBL19527806 | 0.92 | ULK1 (0.40) | BCL6EGFRTBK1 | |
| SCHEMBL19830190 | 0.85 | ULK1 (0.40) | BCL6EGFRITKBTKPRKCQ | |
| SCHEMBL15337488 | 0.83 | EGFR (0.48) | BCL6EGFRITKBTKNCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | BCL6 1014/4885EGFR 2299/4885TBK1 130/4885 |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | BCL6 1014/4885EGFR 2299/4885TBK1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.